Document:

<PAGE>

                                                                   EXHIBIT 10.11

                     PATENT AND TECHNOLOGY LICENSE AGREEMENT

      This twenty-four (24) page AGREEMENT ("AGREEMENT") is made on this 18th
day of October, 2005, by and between THE BOARD OF REGENTS ("BOARD") of THE
UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose
address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY
OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a component institution of
SYSTEM, and BRIDGETECH HOLDINGS INTERNATIONAL, INC., a Delaware corporation
having a principal place of business located at 777 South Highway 101, Suite
215, Solana Beach, California 92075 ("LICENSEE").

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                        Page
<S>                                                                                     <C>
RECITALS .............................................................................     2
I.     EFFECTIVE DATE.................................................................     2
II.    DEFINITIONS....................................................................     2
III.   LICENSE........................................................................     4
IV.    CONSIDERATION, PAYMENTS AND REPORTS............................................     5
V.     SPONSORED RESEARCH.............................................................    10
VI.    PATENTS AND INVENTIONS.........................................................    10
VII.   INFRINGEMENT BY THIRD PARTIES..................................................    11
VIII.  PATENT MARKING.................................................................    12
IX.    INDEMNIFICATION AND INSURANCE..................................................    12
X.     USE OF BOARD AND UTMDACC'S NAME................................................    13
XI.    CONFIDENTIAL INFORMATION AND PUBLICATION.......................................    14
XII.   ASSIGNMENT.....................................................................    15
XIII.  TERM AND TERMINATION...........................................................    15
XIV.   WARRANTY; SUPERIOR-RIGHTS......................................................    18
XV.    GENERAL........................................................................    19
SIGNATURES............................................................................    23
</TABLE>

                                        1

<PAGE>

                                    RECITALS

A.    BOARD owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED
      SUBJECT MATTER developed at UTMDACC.

B.    BOARD, through UTMDACC, desires to have the LICENSED SUBJECT MATTER
      developed in the LICENSED FIELD and used for the benefit of LICENSEE,
      BOARD, SYSTEM; UTMDACC, the inventor(s), and the public as outlined in
      BOARD's Intellectual Property Policy.

C.    LICENSEE wishes to obtain a license from BOARD to practice LICENSED
      SUBJECT MATTER.

      NOW, THEREFORE, in consideration of the mutual covenants and promises
herein contained, the parties agree as follows:

                               I. EFFECTIVE DATE

1.1.  This AGREEMENT is effective as of the date written above ("EFFECTIVE
      DATE"), which is the date fully executed by all parties.

                                 II. DEFINITIONS

      As used in this AGREEMENT, the following terms have the meanings
indicated:

2.1.  AFFILIATE means any business entity more than fifty percent (50%) owned by
      LICENSEE, any business entity which owns more than fifty percent (50%) of
      LICENSEE, or any business entity that is more than fifty percent (50%)
      owned by a business entity that owns more than fifty percent (50%) of
      LICENSEE.

2.2.  LICENSED FIELD means the field of human diagnostics.

2.3.  LICENSED PRODUCTS means any product or service sold by LICENSEE comprising
      LICENSED SUBJECT MATTER pursuant to this AGREEMENT.

                                       2

<PAGE>

2.4.  LICENSED SUBJECT MATTER means inventions and discoveries covered by PATENT
      RIGHTS or TECHNOLOGY RIGHTS within LICENSED FIELD.

2.5.  LICENSED TERRITORY means worldwide.

2.6.  NET SALES means the gross revenues received by LICENSEE and its
      sublicensees from a SALE less sales discounts actually granted, sales
      and/or use taxes actually paid, import and/or export duties actually paid,
      outbound transportation actually prepaid or allowed, and amounts actually
      allowed or credited due to returns (not exceeding the original billing or
      invoice amount), all as recorded by LICENSEE in LICENSEE's official books
      and records in accordance with generally accepted accounting practices and
      consistent with LICENSEE's published financial statements and/or
      regulatory filings with the United States Securities and Exchange
      Commission.

2.7.  PATENT RIGHTS means BOARD's rights in information or discoveries described
      in invention disclosures, or claimed in any patents, and/or patent
      applications, whether domestic or foreign, and all divisionals,
      continuations, continuations-in-part, reissues, reexaminations or
      extensions thereof, and any letters patent that issue thereon as defined
      in Exhibit I attached hereto.

2.8.  SALE OR SOLD means the transfer or disposition of a LICENSED PRODUCT for
      value to a party other than LICENSEE or AFFILIATE.

2.9.  TECHNOLOGY RIGHTS means BOARD's rights in any technical information,
      know-how, processes, procedures, compositions, devices, methods, formulae,
      protocols, techniques, software, designs, drawings or data created by the
      inventor(s) listed in Exhibit I at UTMDACC before the EFFECTIVE DATE,
      which are not claimed in PATENT RIGHTS but that are necessary for
      practicing PATENT RIGHTS.

                                       3

<PAGE>

                                  III. LICENSE

3.1.  BOARD, through UTMDACC, hereby grants to LICENSEE a royalty-bearing,
      exclusive license under LICENSED SUBJECT MATTER to manufacture, have
      manufactured, use, import, offer to sell and/or sell LICENSED PRODUCTS
      within LICENSED TERRITORY for use within LICENSED FIELD. This grant is
      subject to Sections 14.2 and 14.3 hereinbelow, the payment by LICENSEE to
      UTMDACC of all consideration as provided herein, the timely payment of all
      amounts due under any related sponsored research agreement between UTMDACC
      and LICENSEE in effect during this AGREEMENT, and is further subject to
      the following rights retained by BOARD and UTMDACC to:

      (a)   Publish the general scientific findings from research related to
            LICENSED SUBJECT MATTER, subject to the terms of Article
            XI--Confidential Information and Publication; and

      (b)   Use LICENSED SUBJECT MATTER for research, teaching, patient care,
            and other educationally-related purposes.

3.2.  LICENSEE may extend the license granted herein to any AFFILIATE provided
      that the AFFILIATE consents in writing to be bound by this AGREEMENT to
      the same extent as LICENSEE. LICENSEE agrees to deliver such contract to
      UTMDACC within thirty (30) calendar days following execution thereof.

3.3.  LICENSEE may grant sublicenses under LICENSED SUBJECT MATTER consistent
      with the terms of this AGREEMENT provided that LICENSEE is responsible for
      its sublicenses relevant to this AGREEMENT, and for diligently collecting
      all amounts due LICENSEE from sublicensees. If a sublicense pursuant
      hereto becomes bankrupt, insolvent or is placed in the hands of a receiver
      or trustee, LICENSEE, to the extent

                                       4

<PAGE>

      allowed under applicable law and in a timely manner, agrees to use its
      best reasonable efforts to collect all consideration owed to LICENSEE and
      to have the sublicense agreement confirmed or rejected by a court of
      proper jurisdiction.

3.4.  LICENSEE must deliver to UTMDACC a true and correct copy of each
      sublicense granted by LICENSEE, and any modification or termination
      thereof, within thirty (30) calendar days after execution, modification,
      or termination.

3.5.  If this AGREEMENT is terminated pursuant to Article XIII-Term and
      Termination, BOARD and UTMDACC agree to accept as successors to LICENSEE,
      existing sublicensees in good standing at the date of termination provided
      that each such sublicensee consents in writing to be bound by all of the
      terms and conditions of this AGREEMENT.

                    IV. CONSIDERATION, PAYMENTS AND REPORTS

4.1.  In consideration of rights granted by BOARD to LICENSEE under this
      AGREEMENT, LICENSEE agrees to pay UTMDACC the following:

      (a)   All out-of-pocket expenses incurred by UTMDACC in filing,
            prosecuting, enforcing and maintaining PATENT RIGHTS, and all such
            future expenses incurred by UTMDACC, for so long as, and in such
            countries as this AGREEMENT remains in effect. UTMDACC will invoice
            LICENSEE within thirty (30) calendar days of the EFFECTIVE DATE for
            expenses incurred as of that time and on a quarterly basis
            thereafter. The invoiced amounts will be due and payable by LICENSEE
            within thirty (30) calendar days of invoice; and

      (b)   A nonrefundable license documentation fee in the amount of
            $50,000.00. This fee will not reduce the amount of any other payment
            provided for in this ARTICLE IV, and is due and payable within
            thirty (30) calendar days after the

                                       5

<PAGE>

            AGREEMENT has been fully executed by all parties and LICENSEE has
            received an invoice for the amount from UTMDACC; and

      (c)   The following milestone fees, annual maintenance fees, and minimum
            annual royalties:

            Milestone Fees due and payable, regardless of whether LICENSEE or a
            sublicensee achieves each milestone:

            (i)   $50,000.00 upon U.S. FDA approval (or other U.S. regulatory
                  approval) of a LICENSED PRODUCT for human diagnostic use; and

            (ii)  $70,000.00 upon regulatory approval of a LICENSED PRODUCT for
                  human diagnostic use in any country other than the United
                  States; and

            Annual Maintenance Fees and Minimum Royalties due and payable as
            follows:

            (i)   $50,000.00 for the first annual maintenance fee, due and
                  payable within thirty (30) calendar days of the first
                  anniversary of the EFFECTIVE DATE. This fee will not reduce
                  the amount of any other payment provided in this AGREEMENT;
                  and

            (ii)  $75,000.00 for the second annual maintenance fee, due and
                  payable within thirty (30) calendar days of the second
                  anniversary of the EFFECTIVE DATE. This fee will not reduce
                  the amount of any other payment provided in this AGREEMENT;
                  and

            (iii) $90,000.00 for the third annual maintenance fee, due and
                  payable within thirty (30) calendar days of the third
                  anniversary of the EFFECTIVE DATE. This fee will not reduce
                  the amount of any other payment provided in this AGREEMENT;
                  and

                                       6

<PAGE>

            (iv)  Minimum annual royalties of $100,000.00, due and payable
                  quarterly as provided in Section 4.2 beginning upon the first
                  SALE of a LICENSED PRODUCT; and

      (d)   A running royalty equal to five percent (5%) of NET SALES, due and
            payable quarterly as provided in Section 4.2 by LICENSEE to UTMDACC,
            regardless of whether LICENSEE or a sublicensee makes a SALE; and

      (e)   Thirty percent (30%) of all consideration, other than research and
            development money and royalties for NET SALES, received by LICENSEE
            from any sublicensee, including, but not limited to, up-front
            payments, marketing, distribution, franchise, option, license, or
            documentation fees, bonus and milestone payments and equity
            securities.

      (f)   In case of the sale of all of LICENSEE's assets to a third patty,
            this AGREEMENT may be assigned in accordance with the provisions of
            Section 12.1 subject to the payment to UTMDACC of $100,000.00
            license documentation fee prior to the assignment. This fee shall be
            in addition to and shall not replace the license documentation fee
            above. In the event this AGREEMENT is assigned to a third party in
            accordance with the provisions of Section 12.1 in connection with
            any transaction other than sale of all of LICENSEE's assets to a
            third party, thirty percent (30%) of all consideration received from
            the transfer of rights under this AGREEMENT shall be payable to
            UTMDACC (in consideration for UTMDACC allowing the assignment),
            including but not limited to, royalties, up-front payments,
            marketing, distribution, franchise, option, license, or
            documentation fees, bonus and milestone payments and equity
            securities.

                                       7

<PAGE>

4.2.  Unless otherwise provided, all such payments are payable within thirty
      (30) calendar days after March 31, June 30, September 30, and December 31
      of each year during the term of this AGREEMENT, at which time LICENSEE
      will also deliver to UTMDACC a true and accurate report, giving such
      particulars of the business conducted by LICENSEE and its sublicensees, if
      any exist, during the preceding three calendar months under this AGREEMENT
      as necessary for UTMDACC to account for LICENSEE's payments hereunder.
      This report will include pertinent data, including, but not limited to:

      (a)   the accounting methodologies used to account for and calculate the
            items included in the report and any differences in such accounting
            methodologies used by LICENSEE since the previous report; and

      (b)   a list of LICENSED PRODUCTS produced for the three (3) preceding
            calendar months categorized by the technology it relates to under
            PATENT RIGHTS; and

      (c)   the total quantities of LICENSED PRODUCTS produced by the category
            listed in Section 4.2(b); and

      (d)   the total SALES by the category listed in Section 4.2(b); and

      (e)   the calculation of NET SALES by the category listed in Section
            4.2(b); and

      (f)   the royalties so computed and due UTMDACC by the category listed in
            Section 4.2(b) and/or minimum royalties; and

      (g)   all consideration received from each sublicensee or assignee and
            payments due UTMDACC; and

      (h)   all other amounts due UTMDACC herein.

                                       8

<PAGE>

Simultaneously with the delivery of each such report, LICENSEE agrees to pay
UTMDACC the amount due, if any, for the period of such report. These reports are
required even if no payments are due.

4.3.  During the term of this AGREEMENT and for one (1) year thereafter,
      LICENSEE agrees to keep complete and accurate records of its and its
      sublicensees' SALES and NET SALES in sufficient detail to enable the
      royalties and other payments due hereunder to be determined. LICENSEE
      agrees to permit UTMDACC or its representatives, at UTMDACC's expense, to
      periodically examine LICENSEE's books, ledgers, and records during regular
      business hours for the purpose of and to the extent necessary to verify
      any report required under this AGREEMENT. If any amounts due UTMDACC are
      determined to have been underpaid in an amount equal to or greater than
      five percent (5%) of the total amount due during the period so examined,
      then LICENSEE will pay the cost of the examination plus accrued interest
      at the highest allowable rate.

4.4.  Within thirty (30) calendar days following each anniversary of the
      EFFECTIVE DATE, LICENSEE will deliver to UTMDACC, a written progress
      report as to LICENSEE's (and any sublicensee's) efforts and
      accomplishments during the preceding year in diligently commercializing
      LICENSED SUBJECT MATTER in the LICENSED TERRITORY and LICENSEE's (and
      sublicensees') commercialization plans for the upcoming year.

4.5.  All amounts payable hereunder by LICENSEE will be paid in United States
      funds without deductions for taxes, assessments, fees, or charges of any
      kind. Checks are to be made payable to The University of Texas M. D.
      Anderson Cancer Center, and sent by United States mail to Box 297402,
      Houston, Texas 77297, Attention: Manager, Sponsored Programs or by wire
      transfer to:

                                       9

<PAGE>

JPMorgan Chase Bank, N.A.
910 Travis
Houston, Texas 77002
SWIFT: CHASUS33 (for international wires only)
ABA ROUTING NO: 021000021
ACCOUNT NAME: Univ. of Texas M. D. Anderson Cancer Center
ACCOUNT NO.: 1586838979
REFERENCE: include title and EFFECTIVE DATE of AGREEMENT and type of payment
(e.g., license documentation fee, milestone payment, royalty [including
applicable patent application identified by MDA reference number and patent
number or application serial number], or maintenance fee, etc.).

4.6.  No payments due or royalty rates owed under this AGREEMENT will be reduced
      as the result of co-ownership of LICENSED SUBJECT MATTER by BOARD and
      another party, including, but not limited to, LICENSEE.

                             V. SPONSORED RESEARCH

5.1.  If LICENSEE desires to sponsor research for or related to the LICENSED
      SUBJECT MATTER, and particularly where LICENSEE receives payments for
      sponsored research pursuant to a sublicense under this AGREEMENT, LICENSEE
      (a) will notify UTMDACC in writing of all opportunities to conduct this
      sponsored research (including clinical trials, if applicable), (b) will
      solicit research and/or clinical proposals from UTMDACC for this purpose,
      and (c) will give good faith consideration to funding the proposals at
      UTMDACC.

                           VI. PATENTS AND INVENTIONS

6.1.  If after consultation with LICENSEE both parties agree that a new patent
      application should be filed for LICENSED SUBJECT MATTER, UTMDACC will
      prepare and file appropriate patent applications, and LICENSEE will pay
      the cost of searching, preparing, filing, prosecuting and maintaining
      same. If LICENSEE notifies UTMDACC that it does not intend to pay the cost
      of an application, or if LICENSEE does not respond or make an

                                       10

<PAGE>

      effort to agree with UTMDACC on the disposition of rights of the subject
      invention, then UTMDACC may file such application at its own expense and
      LICENSEE's rights to such invention under this AGREEMENT shall terminate
      in their entirety. UTMDACC will provide LICENSEE with a copy of the
      application for which LICENSEE has paid the cost of filing, as well as
      copies of any documents received or filed during prosecution thereof. The
      parties agree that they share a common legal interest to get valid
      enforceable patents and that LICENSEE will keep all privileged information
      received pursuant to this Section confidential.

                       VII. INFRINGEMENT BY THIRD PARTIES

7.1.  LICENSEE, at its expense, must enforce any patent exclusively licensed
      hereunder against infringement in the LICENSED FIELD by third parties and
      is entitled to retain recovery from such enforcement. After reimbursement
      of LICENSEE's reasonable legal costs and expenses related to such
      recovery, LICENSEE agrees to pay UTMDACC either: (a) the royalty detailed
      in Section 4.1(d) for any monetary recovery that is for sales of LICENSED
      PRODUCTS lost due to the infringement and related punitive damages; or (b)
      fifty percent (50%) of reasonable royalties awarded and related punitive
      damages in any recovery in which the award is for reasonable royalties.
      LICENSEE must notify UTMDACC in writing of any potential infringement
      within thirty (30) calendar days of knowledge thereof. If LICENSEE does
      not file suit against a substantial infringer in the LICENSED FIELD within
      six (6) months of knowledge thereof then BOARD or UTMDACC may, at its sole
      discretion, enforce any patent licensed hereunder on behalf of itself and
      LICENSEE, with UTMDACC retaining all recoveries from such enforcement,
      and/or reduce the license granted hereunder to non-exclusive.

                                       11

<PAGE>

7.2.  In any suit or dispute involving an infringer, the parties agree to
      cooperate fully with each other. At the request and expense of the party
      bringing suit, the other party will permit access during regular business
      hours, to all relevant personnel, records, papers, information, samples,
      specimens, and the like in its possession.

                              VIII. PATENT MARKING

8.1.  LICENSEE agrees that all packaging containing individual LICENSED
      PRODUCT(S), documentation therefor, and when possible for actual LICENSED
      PRODUCT(S) sold by LICENSEE, AFFILIATES, and/or sublicensees of LICENSEE
      will be permanently and legibly marked with the number of any applicable
      patent(s) licensed hereunder in accordance with each country's patent
      laws, including Title 35, United States Code.

                       IX. INDEMNIFICATION AND INSURANCE

9.1.  LICENSEE agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC, its
      Regents, officers, employees, students and agents from and against any
      claims, demands, or causes of action whatsoever, costs of suit and
      reasonable attorney's fees, including without limitation, those costs
      arising on account of any injury or death of persons or damage to property
      caused by, or arising out of, or resulting from, the exercise or practice
      of the rights granted hereunder by LICENSEE, its officers, its AFFILIATES
      or their officers, employees, agents or representatives.

9.2.  In no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect,
      special, consequential or punitive damages (including, without limitation,
      damages for loss of profits or expected savings or other economic losses,
      or for injury to persons or property) arising out of, or in connection
      with, this AGREEMENT or its subject matter, regardless of whether BOARD,
      SYSTEM or UTMDACC knows or should how of the possibility of such damages.

                                       12

<PAGE>

9.3.  Beginning at the time when any LICENSED SUBJECT MATTER is being
      distributed or sold (including for the purpose of obtaining regulatory
      approvals) by LICENSEE or by a sublicensee, LICENSEE shall, at its sole
      cost and expense, procure and maintain commercial general liability
      insurance in amounts not less than $2,000,000 per incident and $2,000,000
      annual aggregate, and LICENSEE shall use reasonable efforts to have the
      BOARD, SYSTEM, UTMDACC, its Regents, officers, employees, students and
      agents named as additional insureds. Such commercial general liability
      insurance shall provide: (i) product liability coverage; (ii) broad form
      contractual liability coverage for LICENSEE's indemnification under this
      AGREEMENT; and (iii) coverage for litigation costs. The minimum amounts of
      insurance coverage required herein shall not be construed to create a
      limit of LICENSEE's liability with respect to its indemnification under
      this AGREEMENT.

9.4.  LICENSEE shall provide UTMDACC with written evidence of such insurance
      within thirty (30) days of its procurement. Additionally, LICENSEE shall
      provide UTMDACC with written notice of at least fifteen (15) days prior to
      the cancellation, non-renewal or material change in such insurance.

9.5.  LICENSEE shall maintain such commercial general liability insurance beyond
      the expiration or termination of this AGREEMENT during: (i) the period
      that any LICENSED SUBJECT MATTER developed pursuant to this AGREEMENT is
      being commercially distributed or sold by LICENSEE or by a sublicensee or
      agent of LICENSEE; and (ii) the five (5) year period immediately after
      such period.

                       X. USE OF BOARD AND UTMDACC'S NAME

10.1. LICENSEE will not use the name of (or the name of any employee of)
      UTMDACC, SYSTEM or BOARD in any advertising, promotional or sales
      literature, on its Web site,

                                       13

<PAGE>

      or for the purpose of raising capital without the advance express written
      consent of BOARD secured through:

      The University of Texas
      M. D. Anderson Cancer Center
      Legal Services, Unit 0537
      P.O. Box 301439
      Houston, TX 77230-1439
      ATTENTION:  Natalie Wright
      Email:  nwright@mdanderson.org

      Notwithstanding the above, LICENSEE may use the name of (or name of
      employee of) UTMDACC, SYSTEM or BOARD in routine business correspondence,
      or as needed in appropriate regulatory submissions without express written
      consent.

                  XI. CONFIDENTIAL INFORMATION AND PUBLICATION

11.1. UTMDACC and LICENSEE each agree that all information contained in
      documents marked "confidential" and forwarded to one by the other (i) are
      to be received in strict confidence, (ii) are to be used only for the
      purposes of this AGREEMENT, and (iii) will not be disclosed by the
      recipient party (except as required by law or court order), its agents or
      employees without the prior written consent of the other party, except to
      the extent that the recipient party can establish by competent written
      proof that such information:

      (a)   was in the public domain at the time of disclosure; or

      (b)   later became part of the public domain through no act or omission of
            the recipient party, its employees, agents, successors or assigns;
            or

      (c)   was lawfully disclosed to the recipient party by a third party
            having the right to disclose it; or

      (d)   was already known by the recipient party at the time of disclosure;
            or

                                       14

<PAGE>

      (e)   was independently developed by the recipient party without use of
            the other party's confidential information; or

      (f)   is required by law or regulation to be disclosed.

11.2. Each party's obligation of confidence hereunder will be fulfilled by using
      at least the same degree of care with the other party's confidential
      information as it uses to protect its own confidential information, but
      always at least a reasonable degree of care. This obligation will exist
      while this AGREEMENT is in force and for a period of three (3) years
      thereafter.

11.3. UTMDACC reserves the right to publish the general scientific findings from
      research related to LICENSED SUBJECT MATTER, with due regard to the
      protection of LICENSEE's confidential information. UTMDACC will submit the
      manuscript of any proposed publication to LICENSEE at least thirty (30)
      calendar days before publication, and LICENSEE shall have the right to
      review and comment upon the publication in order to protect LICENSEE's
      confidential information. Upon LICENSEE's request, publication may be
      delayed up to sixty (60) additional calendar days to enable LICENSEE to
      secure adequate intellectual property protection of LICENSEE'S
      confidential information that would otherwise be affected by the
      publication.

                                XII. ASSIGNMENT

12.1. Except in connection with the sale of all of LICENSEE'S assets to a third
      party, this AGREEMENT may not be assigned by LICENSEE without the prior
      written consent of UTMDACC, which will not be unreasonably withheld.

                           XIII. TERM AND TERMINATION

13.1. Subject to Sections 13.3, 13.4 hereinbelow, the term of this AGREEMENT is
      from the EFFECTIVE DATE to the full end of the term or terms for which
      PATENT RIGHTS

                                       15

<PAGE>

      have not expired, or if only TECHNOLOGY RIGHTS are licensed and no PATENT
      RIGHTS are applicable, for a term of fifteen (15) years.

13.2. Any time after three (3) years from the EFFECTIVE DATE, BOARD or UTMDACC
      have the right to terminate this license in any national political
      jurisdiction within the LICENSED TERRITORY if LICENSEE, within ninety (90)
      calendar days after receiving written notice from UTMDACC of the intended
      termination, fails to provide written evidence satisfactory to UTMDACC
      that LICENSEE or its sublicensee(s) has made a SALE of a LICENSED PRODUCT.

13.3. Subject to any rights herein which survive termination, this AGREEMENT
      will earlier terminate in its entirety:

      (a)   automatically, if LICENSEE becomes bankrupt or insolvent and/or if
            the business of LICENSEE shall be placed in the hands of a receiver,
            assignee, or trustee, whether by voluntary act of LICENSEE or
            otherwise; or

      (b)   upon thirty (30) calendar days written notice from UTMDACC, if
            LICENSEE breaches or defaults on the payment or report obligations
            of ARTICLE IV, or use of name obligations of ARTICLE X, unless,
            before the end of the such thirty (30)-calendar day notice period,
            LICENSEE has cured the default or breach to UTMDACC's satisfaction,
            and so notifies UTMDACC, stating the manner of the cure; or

      (c)   upon ninety (90) calendar days written notice from UTMDACC if
            LICENSEE breaches or defaults on any other obligation under this
            AGREEMENT, unless, before the end of the such ninety (90)
            calendar-day notice period, LICENSEE has

                                       16

<PAGE>

            cured the default or breach to UTMDACC's satisfaction and so
            notifies UTMDACC, stating the manner of the cure; or

      (d)   at any time by mutual written agreement between LICENSEE and UTMDACC
            upon one hundred eighty (180) calendar days written notice to all
            parties and subject to any terms herein which survive termination;
            or

      (e)   if Section 13.2 is invoked; or

      (f)   if LICENSEE has defaulted or been late on its payment obligations
            pursuant to the terms of this AGREEMENT on any two (2) occasions in
            a twelve (12) month period.

13.4. Upon termination of this AGREEMENT:

      (a)   nothing herein will be construed to release either party of any
            obligation maturing prior to the effective date of the termination;
            and

      (b)   LICENSEE covenants and agrees to be bound by the provisions of
            Articles IX (Indemnification and Insurance), X (Use of Board and
            UTMDACC's Name) and XI (Confidential Information and Publication) of
            this AGREEMENT; and

      (c)   LICENSEE may, after the effective date of the termination, sell all
            LICENSED PRODUCTS and parts therefor that it has on hand at the date
            of termination, if LICENSEE pays the earned royalty thereon and any
            other amounts due pursuant to Article IV of this AGREEMENT; and

      (d)   Subject to Section 13.4(c), LICENSEE agrees to cease and desist any
            use and all SALE of the LICENSED SUBJECT MATTER and LICENSED
            PRODUCTS upon termination of this AGREEMENT; and

                                       17

<PAGE>

      (e)   LICENSEE grants to BOARD and UTMDACC a nonexclusive royalty bearing
            license with the right to sublicense others with respect to
            improvements made by LICENSEE (including improvements licensed by
            LICENSEE from third parties) in the LICENSED SUBJECT MATTER.
            LICENSEE and UTMDACC agree to negotiate in good faith the royalty
            rate for the nonexclusive license. BOARD's and UTMDACC's right to
            sublicense others hereunder is solely for the purpose of permitting
            others to develop and commercialize the entire technology package.

                         XIV. WARRANTY; SUPERIOR-RIGHTS

14.1. Except for the rights, if any, of the Government of the United States of
      America as set forth below, BOARD represents and warrants its belief that
      (a) it is the owner of the entire right, title, and interest in and to
      LICENSED SUBJECT MATTER, (b) it has the sole right to grant licenses
      thereunder, and (c) it has not knowingly granted licenses thereunder to
      any other entity that would restrict rights granted hereunder except as
      stated herein.

14.2. LICENSEE understands that the LICENSED SUBJECT MATTER may have been
      developed under a funding agreement with the Government of the United
      States of America and, if so, that the Government may have certain rights
      relative thereto. This AGREEMENT is explicitly made subject to the
      Government's rights under any such agreement and any applicable law or
      regulation, including P.L. 96-517 as amended by P.L. 98-620. To the extent
      that there is a conflict between any such agreement, applicable law or
      regulation and this AGREEMENT, the terms of such Government agreement,
      applicable law or regulation shall prevail. LICENSEE agrees that LICENSED
      PRODUCTS used or SOLD in the United States will be manufactured

                                       18

<PAGE>

      substantially in the United States, unless a written waiver is obtained in
      advance from the GOVERNMENT.

14.3. LICENSEE understands and agrees that BOARD and UTMDACC, by this AGREEMENT,
      make no representation as to the operability or fitness for any use,
      safety, efficacy, approvability by regulatory authorities, time and cost
      of development, patentability, and/or breadth of the LICENSED SUBJECT
      MATTER BOARD and UTMDACC, by this AGREEMENT, also make no representation
      as to whether any patent covered by PATENT RIGHTS is valid or as to
      whether there are any patents now held, or which will be held, by others
      or by BOARD or UTMDACC in the LICENSED FIELD, nor do BOARD and UTMDACC
      make any representation that the inventions contained in PATENT RIGHTS do
      not infringe any other patents now held or that will be held by others or
      by BOARD.

14.4. LICENSEE by execution hereof, acknowledges, covenants and agrees that
      LICENSEE has not been induced in any way by BOARD, SYSTEM, UTMDACC or
      employees thereof to enter into this AGREEMENT, and further warrants and
      represents that (a) LICENSEE has conducted sufficient due diligence with
      respect to all items and issues pertaining to this AGREEMENT; and (b)
      LICENSEE has adequate knowledge and expertise, or has used knowledgeable
      and expert consultants, to adequately conduct such due diligence, and
      agrees to accept all risks inherent herein.

                                  XV. GENERAL

15.1. This AGREEMENT constitutes the entire and only agreement between the
      parties for LICENSED SUBJECT MATTER and all other prior negotiations,
      representations, agreements and understandings are superseded hereby. No
      agreements altering or

                                       19

<PAGE>

      supplementing the terms hereof will be made except by a written document
      signed by both parties.

15.2. Any notice required by this AGREEMENT must be given by prepaid, first
      class, certified mail, return receipt requested, and addressed in the case
      of UTMDACC to:

      The University of Texas M. D. Anderson Cancer Center
      Office of Technology Commercialization
      7515 S. Main, Suite 490, Unit 0510
      Houston, Texas 77030
      ATTENTION:      Christopher C. Capelli, M.D.
                      Vice President, Technology Transfer

      with copy to BOARD:

      BOARD OF REGENTS
      The University of Texas System
      201 West Seventh Street
      Austin, Texas 78701
      ATTENTION:      Office of General Counsel

      or in the case of LICENSEE to:

      Bridgetech Holdings International, Inc.
      777 South Highway 101, Suite 215
      Solana Beach, CA 92075
      ATTENTION:      Thomas Kuhn

      or other addresses as may be given from time to time under the terms of
      this notice provision.

15.3. LICENSEE must comply with all applicable federal, state and local laws and
      regulations in connection with its activities pursuant to this AGREEMENT.

15.4. This AGREEMENT will be construed and enforced in accordance with the laws
      of the United States of America and of the State of Texas, without regard
      to its conflict of law provisions. The Texas State Courts of Harris
      County, Texas (or, if there is exclusive federal jurisdiction, the United
      States District Court for the Southern District of Texas)

                                       20

<PAGE>

      shall have exclusive jurisdiction and venue over any dispute arising out
      of this AGREEMENT, and LICENSEE consents to the jurisdiction of such
      courts; however, nothing herein shall be deemed as a waiver by BOARD,
      SYSTEM or UTMDACC of its sovereign immunity.

15.5. Any dispute or controversy arising out of or relating to this AGREEMENT,
      its construction or its actual or alleged breach will be decided by
      mediation. If the mediation does not result in a resolution of such
      dispute or controversy, it will be finally decided by an appropriate
      method of alternate dispute resolution, including without limitation,
      arbitration, conducted in the city of Houston, Harris County, Texas, in
      accordance with the applicable, then-current procedures of the American
      Arbitration Association. The arbitration panel will include members
      knowledgeable in the evaluation of the LICENSED SUBJECT MATTER. Judgment
      upon the award rendered may be entered in the highest court or forum
      having jurisdiction, state or federal. The provisions of this Section 15.5
      will not apply to decisions on the validity of patent claims or to any
      dispute or controversy as to which any treaty or law prohibits such
      arbitration. The decision of the arbitration must be sanctioned by a court
      of law having jurisdiction to be binding upon and enforceable by the
      parties.

15.6. Failure of BOARD or UTMDACC to enforce a right under this AGREEMENT will
      not act as a waiver of right or the ability to later assert that right
      relative to the particular situation involved.

15.7. Headings included herein are for convenience only and will not be used to
      construe this AGREEMENT.
                                       21

<PAGE>

15.8. If any part of this AGREEMENT is for any reason found to be unenforceable,
      all other parts nevertheless will remain enforceable.

                                       22

<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this AGREEMENT.

BOARD OF REGENTS OF THE                    BRIDGETECH HOLDINGS
UNIVERSITY OF TEXAS SYSTEM                 INTERNATIONAL, INC.

By /s/ John Mendelsohn, M.D.               By  /s/ Thomas C. Kuhn III
   ---------------------------------           --------------------------------
        John Mendelsohn, M.D.                  Name: Thomas C. Kuhn III
        President                              Title: EVP & CFO
        The University of Texas
        M.D. Anderson Cancer Center
Date:   10/10/05                           Date: 9/29/05

THE UNIVERSITY OF TEXAS
M.D. ANDERSON CANCER CENTER

By /s/ Leon Leach
   ---------------------------------
        Leon Leach
        Executive Vice President
        The University of Texas
        M.D. Anderson Cancer Center
Date:   10/17/05

Approved as to Content:

By /s/ Christopher C. Capelli, M.D.
   -----------------------------------------
        Christopher C. Capelli, M.D.
        Vice President, Technology Transfer
        M.D. Anderson Cancer Center
Date:   10-6-05

                                       23

<PAGE>

                                    EXHIBIT I

MDA97-041 Synthetic Peptides from Human Papilloma virus (HPV) as Markers of
Protective Immunity and as Reagents for Immunotherapy and Prophylaxis of
HPV-Associated Cervical Cancer. Inventors: Jagannadha K. Sastry, Ph.D.,
Guillermo Tortolero-Luna, M.D., Ph.D., Michele F. Mitchell, M.D.

                                       24<PAGE>

                                                                   EXHIBIT 10.12

                         STRATEGIC PARTNERSHIP AGREEMENT

      THIS STRATEGIC PARTNERSHIP AGREEMENT (this "AGREEMENT"), effective as of
June 7, 2005 (the "EFFECTIVE DATE"), is made by and between BRIDGETECH HOLDINGS
INTERNATIONAL, INC., a Delaware corporation ("BRIDGETECH"), and MARY CROWLEY
MEDICAL RESEARCH CENTER, a Texas non-profit corporation ("CROWLEY"), (Crowley
together with Bridgetech, the "PARTIES").

                                   WITNESSETH

      WHEREAS, CROWLEY is in the business of providing support for the
exploration of investigational vaccine, gene, and cellular therapies with the
goal of expanding treatment options for all cancer patients;

      WHEREAS, BRIDGETECH has established Bridgetech CRO, Inc. ("CRO"), a
clinical research organization research operating in the People's Republic of
China, Hong Kong and the Republic of China (Taiwan); (together known as
"CHINA");

      WHEREAS, the STATE FOOD AND DRUG ADMINISTRATION ("SFDA") is the regulatory
authority of the People's Republic of China responsible for, among other things,
granting authorization for the consumption, manufacture and distribution of
pharmaceutical products in China;

      WHEREAS, the Parties wish to form a strategic partnership in order to
facilitate clinical testing of pharmaceuticals for the purpose of receiving SFDA
approval on said pharmaceutical products for consumption, manufacture and
distribution in China;

      NOW THEREFORE, in consideration of the premises and of the mutual
covenants contained in this Agreement, and for other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, the
Parties agree as follows.

1.    The Project.

      1.1   Purpose. The purpose of this Agreement is to set out the basis on
            which the Parties will:

            (a)   agree to handle the referral of prospective pharmaceutical
                  products identified in Appendix A attached hereto, as the same
                  may be amended from time to time by the mutual written
                  agreement of the Parties (the "PRODUCTS") for the CRO in
                  China;

            (b)   agree on a royalty structure with regards to the revenue
                  generated by the manufacture and distribution of the Products
                  in China;

<PAGE>

                  (all such activities being referred to collectively as the
                  "PROJECT").

2.    Project Terms.

      2.1 Preferred Relationship. Except to the extent prohibited by applicable
      law, rules and regulations:

            (a)   Within China, the CRO shall be the exclusive provider of
                  clinical research services to Crowley during the Project Term,
                  pursuant to the specific terms and conditions of a CRO
                  contract to be negotiated by the Parties with diligence and in
                  good faith.

            (b)   Relative to products comparable in nature, Products referred
                  by Crowley will be afforded the highest priority in terms of
                  scheduling by the CRO during the Project Term.

            (c)   The procedures and protocols provided by Crowley to the CRO
                  for conducting clinical hereunder shall not be used by the CRO
                  to conduct any clinical trials in China for any party other
                  than Crowley, except to the extent that Bridgetech can
                  demonstrate by written evidence that specific procedures or
                  protocols are already matters of general knowledge and
                  practice within the healthcare industry.

      By way of illustration and not by way of limitation, it is the expectation
      of Crowley that the CRO will provide clinical pricing to Crowley according
      to the following template:

      Level 1 Clinical trials - (Oral medication, non toxic) = $250/case/month

      Level 2 Clinical trials - ( IV or Injection, moderate toxicity) =
              $500/case/month

      Level 3 Clinical trials - (Viral Therapies, Immune Therapies,
              BioTherapeutics) = $1000/case/month

      Costs for trials extending past 90 days to be negotiated on a case-by-case
      basis.

      2.2 Oversight. For the Products referred to the CRO by Crowley, Crowley
      will have the right to oversee certain processes and procedures, relative
      to work done with the Products, as may be deemed necessary to ensure
      adherence to Crowley's standards. The Parties agree that such processes
      and procedures, and the oversight rights of Crowley with respect thereto,
      shall be agreed upon in writing within 30 days of the Effective Date and
      shall be attached hereto as Appendix B.

      2.3 Royalties. The Parties agree to the following with regards to
      royalties:

      (a)   For Products Crowley refers to the CRO in which Bridgetech has
            distribution rights in China:

            (i) if the Parties agree that the cost of getting the Product
            through the SFDA approval process is to be borne by Crowley, then
            Bridgetech shall

                                      -2-
<PAGE>

            pay a royalty to Crowley of 40% of all revenues received by
            Bridgetech on the sale of the Product in China;

            (ii) if the Parties agree that the cost of getting the Product
            through the SFDA approval process is not to be borne by Crowley,
            then Bridgetech shall pay a royalty to Crowley of 15% of all
            revenues received by Bridgetech on the sale of the Product in China;
            and

            (iii) if the Parties are not able to agree on who is to bear the
            cost of getting the Product through the SFDA approval process, then
            the Parties shall bear such cost in equal shares, and Bridgetech
            shall pay a royalty to Crowley of 27.5% of all revenues received by
            Bridgetech on the sale of the Product in China.

      2.4 Financial Reports and Payments. Bridgetech shall account to Crowley
      quarterly, within 30 days of the end of each calendar quarter, by
      providing a statement detailing all information necessary to calculate the
      royalties then due to Crowley, together with the payment of any amounts
      then due. Sales in foreign currencies shall be converted into U.S. dollars
      on the last day of the calendar quarter in which such sales occurred.

      2.5 Records; Audits. Bridgetech shall maintain, and shall cause its
      affiliates, contract manufacturers and other agents to maintain all
      records necessary to comply with all applicable laws relating to the
      manufacture, filling, packaging, storage and shipment of Products.
      Bridgetech shall keep and maintain complete and accurate records and books
      of account in sufficient detail and form so as to enable verification of
      royalties or other amounts due pursuant to this Agreement. Bridgetech
      shall maintain such records and books of account for a period of not less
      than three years following the year to which the records pertain. Upon not
      less than 10 days written notice from Crowley, from time to time
      Bridgetech shall allow Crowley or its agent to inspect and copy such
      records and books of account, during reasonable business hours, on
      reasonable advance notice, but in any not more than once per year. In the
      event of underpayment by Bridgetech, Bridgetech shall promptly pay Crowley
      all amounts underpaid, together with interest due on such underpaid
      amounts at an interest rate equal to the then existing prime lending rate
      as published in The Wall Street Journal, or if less, the maximum interest
      rate permitted under applicable law, from the payment due date until the
      actual date of payment. The cost of such audit shall be borne by Crowley,
      unless such audit reveals a discrepancy of greater than ten percent (10%)
      of the total amount determined to be actually due, in which case
      Bridgetech shall bear such cost.

3.    Term and Termination.

      3.1   Term. Unless earlier terminated in accordance with the terms hereof,
            this Agreement will have an initial term of 10 years (the "PROJECT
            TERM"), at the end of which time the Project Term shall
            automatically be extended for additional consecutive one-year terms
            (all such renewal terms shall be considered part of the "Project
            Term"), unless either Party notifies the other no later than 60 days
            before

                                      -3-
<PAGE>

            the end of the then-current Project Term that it does not wish to
            extend the Project Term.

      3.2   Termination Without Cause. If at least one clinical trial has not
            been initiated under this Agreement on or before the first
            anniversary of the Effective Date, then either Party may terminate
            this Agreement, without any further liability or obligation to the
            other Party, by giving the other Party at least 30 days written
            notice of such termination.

      3.3   Termination For Cause. If there occurs a material breach by either
            Party of any representation, warranty, covenant, obligation or other
            provision of this Agreement and such Party fail to cure such breach
            within 30 days after being given written notice thereof by the other
            Party, then the non-breaching Party may, at its option and in
            addition to any other remedies which it may have at law or in
            equity, terminate this Agreement by sending notice of termination in
            writing to the other Party, and such termination shall be effective
            as of the date specified in such notice.

4.    Representations and Warranties.

      4.1   Representations and warranties of the Parties The Parties hereby
            represent and warrant as follows:

            (a)   Status. Bridgetech is a corporation validly existing and in
                  good standing under the laws of the State of Delaware, U.S.A.
                  Bridgetech has all necessary legal power and authority to
                  enter into this Agreement.

            (b)   Status. Crowley is a non-profit corporation duly organized,
                  validly existing and in good standing under the laws of the
                  State of Texas, U.S.A. Crowley has all necessary legal power
                  and authority to enter into this Agreement.

            (c)   Authorization, etc. The execution, delivery and performance by
                  the Parties of this Agreement has been authorized by all
                  necessary action on the part of such entity and its
                  stockholders, as the case may be, and does not and will not

                  (i)   violate the organizational documents of the Parties or
                        any applicable law, or

                  (ii)  contravene, conflict with, or result in a default under
                        any order or judgment of any court or other governmental
                        authority or any agreement to which the Parties may be
                        bound.

            (d)   Enforceability. Its obligations and the obligations of the
                  Parties under this Agreement and any other agreement entered
                  into by such entity in

                                      -4-
<PAGE>

                  connection with this Agreement or the Project are and will be
                  the legal, valid, and binding obligation of the Parties,
                  enforceable against such entity in accordance with its terms,
                  subject to applicable bankruptcy, reorganization, insolvency,
                  moratorium, or similar laws affecting creditors' rights
                  generally and subject as to enforceability, to equitable
                  principle of general application regardless of whether
                  enforcement is sought in a proceeding in equity or at law.

            (e)   Litigation. There are no suits, proceedings, judgments,
                  rulings or orders by or before any governmental authority,
                  court or arbitrator or any pending or threatened action or
                  proceeding affecting the Parties before any governmental
                  authority, court or arbitrator that could reasonably be
                  expected to materially and adversely affect the financial
                  condition or operations of the Parties or the ability of the
                  Parties to perform their respective obligations under this
                  Agreement or any other agreement entered into by such entity
                  in connection with this Agreement or the Project, or which
                  purports to affect the legality, validity or enforceability of
                  this Agreement or any other such agreement.

5.    Confidential Information.

      5.1   Definition. For purposes of this Agreement "CONFIDENTIAL
            INFORMATION" means information provided by a Party to this Agreement
            (the "DISCLOSING PARTY") to any other Party to this Agreement (the
            "RESTRICTED PARTY") in connection with the transactions and
            relationships contemplated by the Project, including but not limited
            to:

            (a)   any data or information that is not generally known to the
                  public, including, but not limited to, products, planning
                  information, marketing strategies, plans, finance operations,
                  sales estimates, business plans, and internal performance
                  results relating to the past, present or future business
                  activities of the Disclosing Party and, services and products
                  provided to or obtained from, the terms of related contracts
                  with, and the identities of any other identifying information
                  regarding the customers, clients and suppliers of the
                  Disclosing Party;

            (b)   any scientific or technical information, design, process,
                  procedure, formula, or improvement that is valuable and secret
                  in the sense that it derives economic value from not being
                  generally known to, and not being readily ascertainable by
                  proper means by, other persons who can obtain economic value
                  from its disclosure or use;

            (c)   all confidential or proprietary concepts, documentation,
                  reports, data (including magnetic tapes), specifications, web
                  sites, screen formats, computer software, source code, object
                  code, flow charts, databases, inventions, systems, system
                  security features, system enhancements,

                                      -5-
<PAGE>

                  information, know-how, show-how and trade secrets, whether or
                  not patentable or copyrightable;

            (d)   all documents, inventions, substances, engineering and
                  laboratory notebooks, drawings, diagrams, specifications,
                  bills of material, equipment, prototypes and models, and any
                  other tangible manifestation of the foregoing;

            (e)   any other information that a Disclosing Party treats as
                  confidential information provided by an affiliate or other
                  third party; and

            (f)   any information derived from any of the foregoing that is
                  treated as confidential.

      5.2   Obligations. Confidential Information belongs to and shall remain
            the property of the Disclosing Party, who shall retain ownership and
            control of its Confidential Information. All Confidential
            Information disclosed or submitted, either orally or in writing
            (including without limitation by electronic means) or through
            observation, by the Disclosing Party to the Restricted Party
            hereunder shall be received and maintained by the Restricted Party
            in strict confidence, shall not be used for any purpose other than
            the purposes expressly permitted by this Agreement and shall not be
            disclosed to any third party other than the Restricted Party's
            directors, officers, employees, agents, consultants and
            representatives that have a need to know such Confidential
            Information to achieve the purposes of this Agreement, provided that
            such Party shall ensure that it and its recipients to whom
            disclosure is to be made are bound by, and take commercially
            reasonable efforts to ensure compliance with, the confidentiality
            terms hereof. Each Party will promptly notify the other upon
            discovery of any unauthorized use or disclosure of the Confidential
            Information.

      5.3   Authorized Disclosure. Each Party may disclose Confidential
            Information hereunder solely to the extent such disclosure is
            reasonably necessary in connection with submissions to any
            governmental authority in connection with this Agreement or in
            filing or prosecuting patent applications contemplated under this
            Agreement, prosecuting or defending litigation, complying with
            applicable laws or for the purposes expressly permitted by this
            Agreement; provided that in the event of any such disclosure of the
            Disclosing Party's Confidential Information by the Restricted Party,
            the Restricted Party will, except where impracticable, give
            reasonable advance notice to the Disclosing Party of such disclosure
            requirement so that the Disclosing Party may seek a protective order
            and or other appropriate remedy or waive compliance with the
            confidentiality provisions of this Article 5, and will use its
            commercially reasonable efforts to secure confidential treatment of
            such Confidential Information required to be disclosed.

                                      -6-
<PAGE>

      5.4   Return of Confidential Information. The Restricted Party shall keep
            Confidential Information belonging to the Disclosing Party in
            appropriately secure locations. Upon the expiration or termination
            of this Agreement, any and all Confidential Information possessed in
            tangible form by a Restricted Party and belonging to the Disclosing
            Party, shall, upon written request, be immediately returned to the
            Disclosing Party (or destroyed if so requested) and not retained by
            the Restricted Party; provided however that a party may retain one
            copy of any Confidential Information in an appropriately secure
            location, which by applicable laws it must retain, for so long as
            such applicable laws require such retention but thereafter shall
            dispose of such retained Confidential Information in accordance with
            applicable laws or this Section.

6.    Press Release and Announcements.

            The Parties that no public release or announcement concerning the
      transactions contemplated hereby shall be issued or made by or on behalf
      of any Party without the prior consent of the other Party, except that
      either Party may, after consultation with counsel, make announcements that
      such Party reasonably may determine are necessary to comply with
      applicable law. Crowley acknowledges and agrees that Bridgetech may be
      required to announce the terms of this Agreement and make publicly
      available this Agreement and that no breach shall be deemed to result
      therefrom. Notwithstanding the foregoing, the Parties cooperate to prepare
      a joint press release to be issued in connection with the execution of
      this Agreement. The Parties further agree that each shall have the right
      to display the others logo on their respective websites.

7.    Indemnification.

      7.1   Indemnification. Each Party (the "INDEMNIFYING PARTY") will defend,
            indemnify, and hold the other Party, it officers, directors,
            shareholders, employees, agents and representatives, and each of its
            and their successors and permitted assigns (the "INDEMNIFIED
            PARTIES"), harmless from and against any and all liabilities,
            judgments, losses, actual damages, costs, and expenses (including
            without limitation reasonable attorneys' and experts' fees) which
            any or all of them may hereafter incur themselves or pay out to
            another by reason of any claim, suit, or proceeding brought by a
            third party, at law or in equity, that arises out of or relates to
            (i) a material breach of any representation, warranty, covenant,
            obligation or other provision of this Agreement by the Indemnifying
            Party, or (ii) any negligence or willful misconduct of the
            Indemnifying Party, except to the extent caused by the gross
            negligence or willful misconduct of an Indemnified Party.

      7.2   Exclusion of Consequential Damages. NOTWITHSTANDING ANYTHING TO THE
            CONTRARY CONTAINED IN THIS AGREEMENT, NEITHER PARTY SHALL, UNDER ANY
            CIRCUMSTANCES, BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS,
            CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE, OR INDIRECT DAMAGES
            ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
            CONTEMPLATED

                                      -7-
<PAGE>

            HEREUNDER, EVEN IF THE PARTY HAS BEEN APPRISED OF THE LIKELIHOOD OF
            SUCH DAMAGES.

8.    Miscellaneous.

      8.1   Binding Effect. This Agreement shall be binding on and inure to the
            benefit of the Parties and their respective successors and permitted
            assigns.

      8.2   Assignment. This Agreement shall not be assigned by either Party
            without the prior written consent of the other Party, not to be
            unreasonably delayed or withheld, and any purported such assignment
            without such consent shall be void. For purposes of this Section
            8.2, a merger involving a Party shall be deemed to result in an
            assignment of this Agreement to the surviving entity in the merger,
            regardless of whether the Party is the surviving entity or merging
            entity to such merger.

      8.3   Notices And Other Communications.

            (a)   Each notice, communication and delivery under this Agreement
                  (i) shall be made in writing signed by the Party making the
                  same, (ii) shall specify the Section of this Agreement
                  pursuant to which it is given, (iii) shall be given either in
                  person or by telecopier, effective upon such delivery or the
                  confirmed transmission and (iv) if not given in person, shall
                  be sent to the applicable Party at the address set forth below
                  (or at such other address as the applicable Party may furnish
                  to the other Party pursuant to this subsection) by
                  international courier delivery service, effective upon the
                  second business day after such notice is deposited, delivery
                  charges pre-paid, with such international courier delivery
                  service. Each Party's notice information is as follows:

            BRIDGETECH:       Bridgetech Holdings International, Inc.
                              777 S. Highway 101, Suite 215
                              Solana Beach, California 92075
                              Attn: Thomas C. Kuhn III
                              Phone: 619-342-7440
                              Fax: 619-342-7497

                              With a copy to:

                              Sutherland Asbill & Brennan LLP
                              999 Peachtree Street, NE
                              Atlanta, Georgia 30309
                              Attn: B. Knox Dobbins
                              Phone: 404-853-8053
                              Fax: 404-853-8806

                                      -8-
<PAGE>

            CROWLEY:          Mary Crowley Medical Research Center
                              3535 Worth Street
                              Collins Building, Suite 302
                              Dallas, Texas 57246
                              Attn: David Shanahan
                              Phone:  214-220-4303
                              Fax:  214-220-4318

      8.4   Severability. If any term or provision of this Agreement, or the
            application thereof to any person or circumstance, shall to any
            extent be contrary to any applicable law or regulation or otherwise
            invalid or unenforceable, the remainder of this Agreement or the
            application of such term or provision to persons or circumstances
            other than those as to which it is contrary, invalid or
            unenforceable shall not be affected thereby and, to the extent
            consistent with the overall intent of this Agreement taken as a
            whole, shall be enforced to the fullest extent permitted by
            applicable law and regulation.

      8.5   Governing Law. The Project Documents will be governed by the laws of
            Delaware except as specifically provided in such documents, without
            regard to principles of conflict of laws.

      8.6   Independent Contractors. The Parties are independent contractors and
            neither Party shall be deemed to be, nor entitled to the benefits
            of, an employee, joint venturer, or partner of the other Party.
            Neither Party is authorized or empowered to act as agent for, or to
            direct or control the day-to-day activities of the other Party for
            any purpose and shall not on behalf of the other Party enter into
            any contract, warranty, or representation as to any matter.

      8.7   Modification; Waiver. This Agreement may not be modified or amended
            except by a document signed by both Parties hereto. No failure of
            either Party to exercise and no delay in exercising any right or
            remedy in connection with this Agreement will operate as a waiver
            thereof, nor will any single or partial exercise of any right
            preclude any other or further exercise of such right or the exercise
            of any other right hereunder.

      8.8   Entire Agreement. This Agreement constitutes the entire
            understanding of the Parties with respect to the subject matter
            hereof. As of the Effective Date, there are no covenants, promises,
            agreements, warranties, representations, conditions or
            understandings, either oral or written, between the parties other
            than as set forth herein. No subsequent alteration, amendment,
            change or addition to this Agreement shall be binding upon the
            parties hereto unless reduced to writing and signed by the
            respective authorized officers of the Parties. The headings are for
            the convenience of the Parties and have no legal or interpretive
            significance whatsoever.

                                      -9-
<PAGE>

      8.9   Additional Actions and Documents. Each of the Parties hereby agrees
            to take or cause to be taken such further actions, to execute,
            acknowledge, deliver and file or cause to be executed, acknowledged,
            delivered and filed such further documents and instruments, and to
            use its best efforts to obtain such consents, as may be necessary or
            as may be reasonably requested in order to fully effectuate the
            purposes, terms and conditions of this Agreement, whether at or
            after the execution of this Agreement.

      8.10  Counterparts. This Agreement may be executed in counterparts, each
            of which shall be deemed an original, but all of which together
            shall constitute one and the same instrument.

                       (Signatures on the following page)

                                      -10-
<PAGE>

IN WITNESS WHEREOF, the Parties have executed this Agreement, or caused it to be
executed by their duly authorized officers or agents all as of the day and year
first above written.

                                         BRIDGETECH HOLDINGS
                                         INTERNATIONAL, INC.

                                         By:    /s/ Thomas C. Kuhn III
                                                ----------------------------
                                         Name:  Thomas C. Kuhn III
                                         Title: EVP & CFO

                                         MARY CROWLEY MEDICAL RESEARCH
                                         CENTER

                                         By:    /s/ David Shanahan
                                                ----------------------------
                                         Name:  David Shanahan
                                         Title: President

                                      -11-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]